vorasidenib
servier
['vorasidenib', 'indigo']
 and i were extremely impressed with the data from the phase iii indigo study investigating vorasidenib in grade 2 idh-mutant gliomas at #asco23. this indication currently has very limited options; an approval for vorasidenib could be huge for these patients.
Healthcare Analyst at @Datamonitor_HC, Citeline. All views are my own.